Patents by Inventor Antonello Pileggi

Antonello Pileggi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200239884
    Abstract: Disclosed herein are methods for treating/and or preventing diabetes using a specific inhibitor of SMAD7 expression or function. Also disclosed are methods of promoting organ and/or cell, e.g., pancreatic islet cell, survival after transplantation using a specific inhibitor of SMAD7 expression or function.
    Type: Application
    Filed: September 4, 2019
    Publication date: July 30, 2020
    Inventors: Giovanni Monteleone, Peter Buchwald, Luca Inverardi, Antonello Pileggi, Camillo Ricordi, Alice Tomei
  • Patent number: 10443056
    Abstract: Disclosed herein are methods for treating/and or preventing diabetes using a specific inhibitor of SMAD7 expression or function. Also disclosed are methods of promoting organ and/or cell, e.g., pancreatic islet cell, survival after transplantation using a specific inhibitor of SMAD7 expression or function.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: October 15, 2019
    Assignees: Nogra Pharma Limited, University of Miami
    Inventors: Giovanni Monteleone, Peter Buchwald, Luca Inverardi, Antonello Pileggi, Camillo Ricordi, Alice Tomei
  • Publication number: 20190136237
    Abstract: Disclosed herein are methods for treating/and or preventing diabetes using a specific inhibitor of SMAD7 expression or function. Also disclosed are methods of promoting organ and/or cell, e.g., pancreatic islet cell, survival after transplantation using a specific inhibitor of SMAD7 expression or function.
    Type: Application
    Filed: August 10, 2018
    Publication date: May 9, 2019
    Inventors: Giovanni Monteleone, Peter Buchwald, Luca Inverardi, Antonello Pileggi, Camillo Ricordi, Alice Tomei
  • Patent number: 10081809
    Abstract: Disclosed herein are methods for treating/and or preventing diabetes using a specific inhibitor of SMAD7 expression or function. Also disclosed are methods of promoting organ and/or cell, e.g., pancreatic islet cell, survival after transplantation using a specific inhibitor of SMAD7 expression or function.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: September 25, 2018
    Assignees: University of Miami, Nogra Pharma Limited
    Inventors: Giovanni Monteleone, Peter Buchwald, Luca Inverardi, Antonello Pileggi, Camillo Ricordi, Alice Tomei
  • Patent number: 9980923
    Abstract: A stable liquid nanoemulsion of a volatile gas anesthetic, such as, isoflurane or sevoflurane, is disclosed which is effective in inducing and maintaining a state of anesthesia and/or general anesthesia in a patent. A method of preparation of stable liquid formulations of volatile gas anesthetics is presented, as well as a method for directly testing the concentration of a volatile gas anesthetic in a stable liquid formulation. A kit comprising an amount of a stable liquid formulation of a volatile gas anesthetic, and the non-specialized equipment for administration of the same to a patient, either in an operating room environment or in the field, is also described herein.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: May 29, 2018
    Assignee: University of Miami
    Inventors: Ernesto Pretto, Jr., Camillo Ricordi, Kyota Fukazawa, Antonello Pileggi, Christopher Fraker
  • Publication number: 20160263051
    Abstract: A stable liquid nanoemulsion of a volatile gas anesthetic, such as, isoflurane or sevoflurane, is disclosed which is effective in inducing and maintaining a state of anesthesia and/or general anesthesia in a patent. A method of preparation of stable liquid formulations of volatile gas anesthetics is presented, as well as a method for directly testing the concentration of a volatile gas anesthetic in a stable liquid formulation. A kit comprising an amount of a stable liquid formulation of a volatile gas anesthetic, and the non-specialized equipment for administration of the same to a patient, either in an operating room environment or in the field, is also described herein.
    Type: Application
    Filed: March 9, 2016
    Publication date: September 15, 2016
    Inventors: Ernesto Pretto, Camillo Ricordi, Kyota Fukazawa, Antonello Pileggi, Christopher Fraker
  • Patent number: 9308269
    Abstract: A stable liquid nanoemulsion of a volatile gas anesthetic, such as, isoflurane or sevoflurane, is disclosed which is effective in inducing and maintaining a state of anesthesia and/or general anesthesia in a patent. A method of preparation of stable liquid formulations of volatile gas anesthetics is presented, as well as a method for directly testing the concentration of a volatile gas anesthetic in a stable liquid formulation. A kit comprising an amount of a stable liquid formulation of a volatile gas anesthetic, and the non-specialized equipment for administration of the same to a patient, either in an operating room environment or in the field, is also described herein.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: April 12, 2016
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Ernesto Pretto, Jr., Camillo Ricordi, Kyota Fukazawa, Antonello Pileggi, Christopher Fraker
  • Publication number: 20150315573
    Abstract: Disclosed herein are methods for treating/and or preventing diabetes using a specific inhibitor of SMAD7 expression or function. Also disclosed are methods of promoting organ and/or cell, e.g., pancreatic islet cell, survival after transplantation using a specific inhibitor of SMAD7 expression or function.
    Type: Application
    Filed: April 18, 2013
    Publication date: November 5, 2015
    Applicants: UNIVERSITY OF MIAMI, NOGRA PHARMA LIMITED
    Inventors: Giovanni Monteleone, Peter Buchwald, Luca Inverardi, Antonello Pileggi, Camillo Ricordi, Alice Tomei
  • Publication number: 20140256828
    Abstract: A stable liquid nanoemulsion of a volatile gas anesthetic, such as, isoflurane or sevoflurane, is disclosed which is effective in inducing and maintaining a state of anesthesia and/or general anesthesia in a patent. A method of preparation of stable liquid formulations of volatile gas anesthetics is presented, as well as a method for directly testing the concentration of a volatile gas anesthetic in a stable liquid formulation. A kit comprising an amount of a stable liquid formulation of a volatile gas anesthetic, and the non-specialized equipment for administration of the same to a patient, either in an operating room environment or in the field, is also described herein.
    Type: Application
    Filed: July 26, 2012
    Publication date: September 11, 2014
    Applicant: University of Miami
    Inventors: Ernesto Pretto, JR., Camillo Ricordi, Kyota Fukazawa, Antonello Pileggi, Christopher Fraker
  • Patent number: 8702684
    Abstract: A device (10) for receiving implanted biological material includes a mechanoprotective surface (16) defining an adjacent space, an assembly (26, 28) for locally delivering media to said space, and a pump or slow/sustained release reservoir structure (14) operatively coupled to the assembly. The device may comprise an additional plunger body for being disposed in said space. The implanted biological material may be encapsulated or non-encapsulated.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: April 22, 2014
    Assignees: University of Miami, Converge Biotech Inc.
    Inventors: Nicholas Bodor, Peter Buchwald, Christopher A. Fraker, Jeffrey Hubbell, Luca Inverardi, Norma Sue Kenyon, Paul Latta, Antonello Pileggi, Cheryl Stabler Anderson, Fabio Grassi, Camillo Ricordi
  • Publication number: 20130089594
    Abstract: The present invention provides highly porous, biocompatible and biostable scaffold constructs for improving overall cell engraftment, survival, function and long-term viability. These scaffolds can provide mechanical protection to implanted cells, afford retrievability from a subject, and allow for both intra-device vascularization and a means to spatially distribute the cells within the device. The scaffold surface or material may be modified with one or more different adhesion proteins and optionally other biological factors for enhanced cell adherence and viability. Further, the scaffold surface or material may be modified with one or more agents with slow/sustained release characteristics to aid engraftment, survival, function or long-term viability. Implanted cells of the invention may be insulin-producing cells such as islets.
    Type: Application
    Filed: April 12, 2011
    Publication date: April 11, 2013
    Applicants: CONVERGE BIOTECH INC., UNIVERSITY OF MIAMI
    Inventors: Cheryl Stabler Anderson, Eileen Pedraza, Christopher A. Fraker, Peter Buchwald, Norma Sue Kenyon, Luca Inverardi, Antonello Pileggi, Paul Latta, Jeffrey Hubbell, Jessica Weaver, Camillo D. Ricordi
  • Publication number: 20100204683
    Abstract: A device (10) for receiving implanted biological material includes a mechanoprotective surface (16) defining an adjacent space, an assembly (26, 28) for locally delivering media to said space, and a pump or slow/sustained release reservoir structure (14) operatively coupled to the assembly. The device may comprise an additional plunger body for being disposed in said space. The implanted biological material may be encapsulated or non-encapsulated.
    Type: Application
    Filed: February 1, 2008
    Publication date: August 12, 2010
    Inventors: Nicholas Bodor, Peter Buchwald, Christopher A. Fraker, Jeffrey Hubbell, Luca Inverardi, Norma Sue Kenyon, Paul Latta, Antonello Pileggi, Cheryl Stabler Anderson, Fabio Grassi, Camillo Ricordi